Table III.

Key findings

Intravenous immunoglobulins (IVIg) represent a valid treatment option for rare immune dermatoses. In recalcitrant disease courses, adjuvant IVIg therapy can be attempted. It is often effective and well-tolerated, with a good safety profile. Because of high treatment costs and the lack of approval, IVIg therapy is based on the discussion between the physician, the patient and the respective health insurance. At a given indication, reimbursement should be requested from health insurance. The standard IVIg dosage may be reduced and/or intervals stretched. These may be equally effective and better tolerated. Therapy response and tolerability differ between the individual patients and different diseases and must be monitored carefully. Standardized documentation on the use of IVIg in especially rare dermatological diseases is warranted.